ADB-102 is our lead development program for the treatment of Chronic Knee Osteoartritis Pain. Our novel, non-opioid JDNI8 rdHSV-CA8* non-toxic gene therapy (ADLR-1001) is designed to locally target through intra-articular (inside the knee joint) the peripheral sensory nerve fibers that are sensitized in OA patients to treat their complex (eg: neuropathic and inflammatory) pain disorder.

NIH UG3/UH3 HEAL grant funds development of ADB-102 Program through IND and First-in-Human clinical study. Scope of Award includes manufacturing/process development, CMC, and formal GLP toxicology studies.

Validation in Osteoarthritis Knee Pain Opens Pipeline Expansion Opportunities into Additional High-Value Osteoarthritis Indications

Osteoarthritis (OA) Knee Pain

OA knee pain is a common degenerative joint condition characterized by the breakdown of cartilage in the knee joints. This leads to pain, stiffness, and reduced mobility, particularly during activities like walking or climbing stairs. Current treatment options involve a combination of lifestyle modifications, pain relievers, and, in severe cases, surgical interventions like knee replacement to alleviate symptoms and improve quality of life.

• ~700,000 knee replacements annually

• Limited pain ​treatment options

• 50% have knee osteoarthritis (16 million patients)

• Median onset at age 55, ~60% female

• 70%-80% of patients develop bilateral OA over 10-12 years

Other Joints: Hip, Shoulder, etc.

• ~400,000 hip replacements annually in the U.S.

• Many patients are not surgical candidates

  • • Acetaminophen / NSAIDs​
    • Steroids​
    • Opioids
    • Hyaluronate Injections​
    • Knee Replacement

1. CDC: https://www.cdc.gov/arthritis/basics/osteoarthritis